[go: up one dir, main page]

DK2018153T3 - Flydende orale sammensætninger - Google Patents

Flydende orale sammensætninger

Info

Publication number
DK2018153T3
DK2018153T3 DK07732588.4T DK07732588T DK2018153T3 DK 2018153 T3 DK2018153 T3 DK 2018153T3 DK 07732588 T DK07732588 T DK 07732588T DK 2018153 T3 DK2018153 T3 DK 2018153T3
Authority
DK
Denmark
Prior art keywords
aqueous suspension
simvastatin
agent
oral compositions
liquid oral
Prior art date
Application number
DK07732588.4T
Other languages
English (en)
Inventor
Phillip Driver
Original Assignee
Rosemont Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosemont Pharmaceuticals Ltd filed Critical Rosemont Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK2018153T3 publication Critical patent/DK2018153T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A63—SPORTS; GAMES; AMUSEMENTS
    • A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
    • A63B21/00—Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices
    • A63B21/02—Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices using resilient force-resisters
    • A—HUMAN NECESSITIES
    • A63—SPORTS; GAMES; AMUSEMENTS
    • A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
    • A63B2225/00—Miscellaneous features of sport apparatus, devices or equipment
    • A63B2225/09—Adjustable dimensions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Education & Sports Medicine (AREA)
DK07732588.4T 2006-04-26 2007-04-26 Flydende orale sammensætninger DK2018153T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74565306P 2006-04-26 2006-04-26
PCT/GB2007/001552 WO2007125339A1 (en) 2006-04-26 2007-04-26 Liquid oral compositions

Publications (1)

Publication Number Publication Date
DK2018153T3 true DK2018153T3 (da) 2012-07-23

Family

ID=38520565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07732588.4T DK2018153T3 (da) 2006-04-26 2007-04-26 Flydende orale sammensætninger

Country Status (13)

Country Link
US (2) US9597289B2 (da)
EP (1) EP2018153B1 (da)
JP (1) JP2009534459A (da)
CN (1) CN101431982A (da)
AT (1) ATE552825T1 (da)
AU (1) AU2007245410A1 (da)
CY (1) CY1112917T1 (da)
DK (1) DK2018153T3 (da)
ES (1) ES2385752T3 (da)
PL (1) PL2018153T3 (da)
PT (1) PT2018153E (da)
SI (1) SI2018153T1 (da)
WO (1) WO2007125339A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007125339A1 (en) * 2006-04-26 2007-11-08 Rosemont Pharmaceuticals Ltd Liquid oral compositions
GB2497728A (en) * 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
CN104586761A (zh) * 2013-10-30 2015-05-06 上海信谊药厂有限公司 辛伐他汀纳米混悬剂及其制备方法
JP6832195B2 (ja) * 2016-03-03 2021-02-24 ライオン株式会社 経口液剤及び経口固形剤
WO2017212409A1 (en) * 2016-06-08 2017-12-14 Ftf Pharma Private Limited A novel pharmaceutical composition of a lipid lowering compound
GB201704687D0 (en) 2017-03-24 2017-05-10 Wockhardt Uk Ltd Pharmaceutical composition of simvastatin or salt thereof
CN108403630A (zh) * 2018-05-31 2018-08-17 佛山市南海东方澳龙制药有限公司 混悬剂及其制备方法
CN110812326B (zh) * 2019-11-04 2022-04-22 黑龙江省农业科学院畜牧兽医分院 一种辛伐他汀混悬乳剂及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
IL123902A (en) * 1995-11-02 2003-01-12 Warner Lambert Co PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR
DE19541260A1 (de) * 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US20050038102A1 (en) 1997-10-14 2005-02-17 Brigham And Womens Hospital Upregulation of type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
EP0940395A1 (en) * 1998-03-05 1999-09-08 Synthon B.V. Process for producing simvastatin and/or its derivatives
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
CA2240983A1 (en) * 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
US20010006656A1 (en) 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
US6696086B1 (en) * 1999-09-10 2004-02-24 Lek Pharmaceuticals D.D. Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
WO2001034590A1 (en) * 1999-11-11 2001-05-17 Biocon India Limited Process for manufacturing simvastatin and the novel intermediates
FR2801508B1 (fr) 1999-11-29 2003-11-14 Oreal Utilisation d'inhibiteurs d'hmg coa-reductase pour le traitement de la seborrhee
US6534537B2 (en) * 2000-01-07 2003-03-18 Kenneth Weisman Use of HMG-COA reductase inhibitors to prevent and treat BPH
JP3946521B2 (ja) * 2000-03-30 2007-07-18 チェイル ジェダン コーポレイション シンバスタチンの製造方法
US6806290B2 (en) * 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
EP1303268A4 (en) * 2000-07-27 2006-08-09 Plus Chemicals Bv HIGHLY PURIFIED COMPOSITIONS BASED ON SIMVASTATIN
DE10057648A1 (de) 2000-11-21 2002-06-06 Univ Jw Goethe Frankfurt Main Verwendung von Inhibitoren von 3-Hydroxyl-3-methylglutaryl-Coenzym-A-Reduktase
WO2002047682A1 (fr) 2000-12-14 2002-06-20 Sankyo Company, Limited Composition ameliorant les lipides sanguins
WO2001045484A2 (en) * 2001-02-27 2001-06-28 Chong Kun Dang Pharmaceutical Corp. An improved process for preparing simvastatin
JP2004535370A (ja) * 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 味をマスクした液体製薬学的組成物
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
US6797831B2 (en) * 2001-05-18 2004-09-28 Aurobindo Pharma Limited Process for lactonization to produce simvastatin
WO2002094803A1 (en) * 2001-05-18 2002-11-28 Aurobindo Pharma Limited A process for lactonization to produce highly pure simvastatin
DE60219307T2 (de) 2001-06-12 2008-01-10 Galephar M/F Oral anzuwendende arzneizusammensetzung enthaltend ein statinderivat
FR2827770B1 (fr) 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
US20030060501A1 (en) 2001-09-19 2003-03-27 Francois Mach Facilitating tissue grafts with statins (HMG-COa reductase inhibitors)
US6709600B2 (en) 2001-09-21 2004-03-23 The Regents Of The University Of California Method for removing organic liquids from aqueous solutions and mixtures
US20040142902A1 (en) 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US20040018248A1 (en) 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
AU2002364146A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Pharmaceutical suspension for oral administration
US20030162827A1 (en) 2002-01-30 2003-08-28 Suresh Venkataram HMG CoA reductase inhibiting composition, method of preparation thereof and method for competitively inhibiting HMG CoA reductase using such composition
ES2192988B1 (es) 2002-02-28 2005-02-16 Jose Manuel Quesada Gomez Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.
US7074825B2 (en) 2002-03-07 2006-07-11 Huanbiao Mo Composition and method for treating cancer
US6603022B1 (en) * 2002-05-10 2003-08-05 Biocon India Limited Process for manufacturing Simvastatin and novel intermediates thereof
AU2003245313A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20050182106A1 (en) 2002-07-11 2005-08-18 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocysteine
AU2003281176A1 (en) * 2002-07-11 2004-02-02 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocystein
US20050182036A1 (en) 2002-08-02 2005-08-18 Sankyo Company, Limited Medicinal composition containing an HMG-CoA reductase inhibitor
US20050187204A1 (en) 2002-08-08 2005-08-25 Sankyo Company, Limited Medicinal composition for lowering blood lipid level
CA2497832A1 (en) 2002-09-03 2004-03-18 Biovail Laboratories International Srl Pharmaceuticals formulations and methods for modified release of statin drugs
AU2003270487A1 (en) 2002-09-11 2004-04-30 The Board Of Trustees Of The University Of Arkansas Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin
CN100486572C (zh) * 2002-11-04 2009-05-13 饶品昌 他汀类药物新剂型
US6995277B2 (en) * 2003-02-11 2006-02-07 Plus Chemicals, B.V. Process for preparing simvastatin having controlled ranges of simvastatin dimer content
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050192340A1 (en) 2003-11-05 2005-09-01 Moshe Flashner-Barak Simvastatin formulations and methods of making same
WO2005053683A1 (en) 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
EP1563837A1 (en) 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
ATE404189T1 (de) 2004-04-26 2008-08-15 Alcon Inc Statine zur behandlung von okularer hypertonie und glaukom
US20050267197A1 (en) 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
JP2006022039A (ja) * 2004-07-08 2006-01-26 Towa Yakuhin Kk 高い安定性を有するシンバスタチン固形製剤
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
WO2007125339A1 (en) * 2006-04-26 2007-11-08 Rosemont Pharmaceuticals Ltd Liquid oral compositions
AU2008311053B2 (en) * 2007-10-09 2012-08-30 Novartis Ag Pharmaceutical formulation of valsartan

Also Published As

Publication number Publication date
WO2007125339A1 (en) 2007-11-08
US20170143669A1 (en) 2017-05-25
AU2007245410A1 (en) 2007-11-08
US10300041B2 (en) 2019-05-28
EP2018153A1 (en) 2009-01-28
PT2018153E (pt) 2012-07-04
ATE552825T1 (de) 2012-04-15
SI2018153T1 (sl) 2012-08-31
PL2018153T3 (pl) 2012-09-28
JP2009534459A (ja) 2009-09-24
US9597289B2 (en) 2017-03-21
CN101431982A (zh) 2009-05-13
EP2018153B1 (en) 2012-04-11
US20090311330A1 (en) 2009-12-17
CY1112917T1 (el) 2016-04-13
ES2385752T3 (es) 2012-07-31

Similar Documents

Publication Publication Date Title
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
MX2009004767A (es) Preparacion liquida que comprende un complejo de pimobendan y ciclodextrina.
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2010529999A5 (da)
MX2010003923A (es) Formulacion farmaceutica de valsartan.
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
TW200600118A (en) Pharmaceutical suspension composition
MX348936B (es) Formulaciones de antibioticos, dosis unitarias, equipos y metodos.
JP2009531457A5 (da)
TW200716202A (en) Pediatric formulation of topiramate
FR2906140B1 (fr) Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
ES2720954T3 (es) Formulaciones estabilizadas de estatina
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
WO2009064681A3 (en) Liquid compositions comprising valsartan
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
MX2010001092A (es) Composicion farmaceutica liquida estable basada en trazodona.
RS52150B (en) PELLETS CONTAINING VENLAFAKSIN HYDROCHLORIDE
WO2008114859A1 (ja) ピラゾール誘導体を含有する医薬組成物
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
FI3554474T3 (fi) Mikafungiinikoostumuksia
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
CY1120050T1 (el) Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων